CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
基本信息
- 批准号:6107310
- 负责人:
- 金额:$ 3.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-08-01 至 1999-07-31
- 项目状态:已结题
- 来源:
- 关键词:Klebsiella pneumoniae antibacterial agents beta lactamase cephalosporins drug resistance gene expression gene mutation genetic strain human tissue molecular cloning nosocomial infections nucleic acid hybridization nucleic acid sequence plasmids polymerase chain reaction pulsed field gel electrophoresis serology /serodiagnosis southern blotting
项目摘要
The introduction of highly stable Extended-Spectrum cephalosporins
at the beginning of the 1980's was quickly followed by the
emergence of several cephalosporin resistant Extended-Spectrum
beta-lactamases identified among clinical isolates of Klebsiella
pneumoniae. Homology studies of these enzymes suggested that
bacterial have adapted to the antibiotics by altering (amino acid
substitutions) existing plasmid-mediated beta-lactamases such to
expand their spectrum of activity. Subsequently, plasmids encoding
altered beta-lactamases were disseminated among gram-negative
clinical isolates. This resulted in increased beta-lactam antibiotic
resistance among clinical gram-negative bacteria. In this proposal,
an extensive investigation will be conducted to identify and
characterize novel beta-lactamases (derrived from amino acid
substitutions) identified in clinical isolates of Klebsiella
pneumoniae. Cephalosporin resistant Klebsiella pneumonia will be
identified by Kirby-Bauer disk diffusion susceptibility testing using
disk impregnated with cephalosporins (ceftazidime, cefotaxime, and
ceftriaxone). Isolates demonstrating Extended-Spectrum activity are
conjugated with susceptible E. Coli recipients to identify
transmissible beta-lactam resistance genes Transconjugates are
screened for the presence of TEM or SHV-type beta-lactamase
genes by polymerase chain reaction and Southern blot
hybridizations. Products obtained by PCR are sequenced to identify
novel mutations. Clones harboring mutations are cloned and
resequenced to confirm original findings. Data obtained from this
proposal will be instrumental in (1) the early detection of mutant
TEM and SHV-type beta-lactamases for proper treatment, (2)
maximizing the use of antibiotics currently available, (3)
establishing new forms of treatment, and (4) elucidating the trends
and mechanisms of drug resistance and transmission of TEM and
SHV-type beta-lactamases during nosocomial outbreaks. This
project will involve students in every aspect. Students will gain
invaluable knowledge and training in the fundamentals of DNA
manipulations, PCR technology, analysis of clinical samples, DNA
sequencing, data collection, and manuscript preparation. Training
obtained from this study will prepare students for doctoral studies in
cell, molecular, and microbiology.
高稳定超广谱头孢菌素的介绍
在20世纪80年代初,S很快就被
几种头孢菌素耐药超广谱菌株的出现
临床分离克雷伯菌中的β-内酰胺酶
肺炎。对这些酶的同源性研究表明
细菌通过改变(氨基酸)来适应抗生素
替换)现有的质粒介导的β-内酰胺酶
扩大他们的活动范围。随后,编码的质粒
革兰氏阴性菌中传播的β-内酰胺酶变异
临床分离株。这导致了β-内酰胺类抗生素的增加
临床革兰氏阴性菌的耐药性分析。在这份提案中,
将进行广泛的调查,以确定和
新型β-内酰胺酶的特性(来源于氨基酸)
在临床分离的克雷伯氏菌中发现的
肺炎。对头孢菌素耐药的肺炎克雷伯菌
经Kirby-Bauer纸片扩散敏感性试验鉴定
头孢菌素(头孢他啶、头孢噻肟和
头孢曲松)。表现出广谱活性的分离株是
与敏感的大肠杆菌受体结合以识别
可传播的β-内酰胺类耐药基因转接物为
TEM型或SHV型β-内酰胺酶的筛查
聚合酶链式反应和Southern杂交检测基因
混血。通过聚合酶链式反应获得的产物进行测序以鉴定
新的突变。含有突变的克隆被克隆并
重新测序以确认最初的发现。从本网站获得的数据
建议将有助于(1)突变的早期检测
适当治疗的TEM和SHV型β-内酰胺酶,(2)
最大限度地使用现有抗生素,(3)
建立新的治疗形式,以及(4)阐明趋势
以及耐药机制和传播机制。
医院暴发流行的SHV型β-内酰胺酶这
项目将涉及到学生的方方面面。学生将受益
无价的DNA基础知识和培训
操作、聚合酶链式反应技术、临床样本分析、DNA
测序、数据收集和手稿准备。培训
这项研究将使学生为博士学习做好准备
细胞、分子和微生物学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Edward Raynor其他文献
James Edward Raynor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James Edward Raynor', 18)}}的其他基金
U-RISE Program at Fayetteville State University
费耶特维尔州立大学 U-RISE 项目
- 批准号:
10599070 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
8508947 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
7761411 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
8248165 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
MBRS Research Initiative for Scientific Enhancement
MBRS 科学增强研究计划
- 批准号:
8855779 - 财政年份:2002
- 资助金额:
$ 3.95万 - 项目类别:
CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
- 批准号:
6338812 - 财政年份:2000
- 资助金额:
$ 3.95万 - 项目类别:
CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
- 批准号:
6204152 - 财政年份:1999
- 资助金额:
$ 3.95万 - 项目类别:
CHARACTERIZATION OF CEFTAZIDIME RESISTANCE IN KLEBSIELLA PNEUMONIAE
肺炎克雷伯菌对头孢他啶耐药的特征
- 批准号:
6240237 - 财政年份:1997
- 资助金额:
$ 3.95万 - 项目类别:
相似海外基金
Development of rapid detection method for drug-resistant bacteria in pulmonary MAC disease and search for new antibacterial agents
肺部MAC疾病耐药菌快速检测方法的建立及新型抗菌药物的寻找
- 批准号:
23K07930 - 财政年份:2023
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of novel antibacterial agents using crystal structure-based drug screening
利用基于晶体结构的药物筛选开发新型抗菌剂
- 批准号:
23K07918 - 财政年份:2023
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections
ATP 合酶作为针对耐药细菌感染的广谱抗菌药物临床前开发的新兴靶标
- 批准号:
472342 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Operating Grants
Clinical application of a rapid assay for antibacterial susceptibility test of beta-lactams and carbapenems antibacterial agents using MALDI-TOF MS
MALDI-TOF MS快速测定β-内酰胺类和碳青霉烯类抗菌药物药敏试验的临床应用
- 批准号:
22K07406 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tailored and uniform fibre-like micelles as antibacterial agents.
定制且均匀的纤维状胶束作为抗菌剂。
- 批准号:
569719-2022 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Postgraduate Scholarships - Doctoral
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
- 批准号:
531450-2018 - 财政年份:2022
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
- 批准号:
521908-2018 - 财政年份:2021
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
- 批准号:
531450-2018 - 财政年份:2021
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
- 批准号:
521908-2018 - 财政年份:2020
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents.
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体。
- 批准号:
531450-2018 - 财政年份:2020
- 资助金额:
$ 3.95万 - 项目类别:
Collaborative Research and Development Grants














{{item.name}}会员




